MDNA - Medicenna announces ATM sales facility for $25M

Medicenna Therapeutics (MDNA) has entered into a sales agreement with SVB Leerink, pursuant to which the Company may, from time to time sell, through ATM offerings on Nasdaq for an aggregate offering price of up to $25M. The Company plans to use the net proceeds of the ATM Offering, if any, for general corporate purposes including, but not limited, to working capital expenditures, research and development expenditures, and clinical trial expenditures. The ATM Offering will terminate upon the earlier of the $25M sale of common shares or the termination of the sales agreement or August 28, 2022. MDNA +3% after hours to $5.05Source: Press Release

For further details see:

Medicenna announces ATM sales facility for $25M